Physician profile
Walter Brandner
NPI 1932115763
$9,485.87
in general payments reported to CMS, 2019-2025
39 companies · $86.44 in 2025
The $86.44 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $1,932 · 2021: $2,139 · 2022: $1,930 · 2023: $1,451 · 2024: $384 · 2025: $86.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,611.20 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $952.88 | 2020-2024 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $764.33 | 2019-2023 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $743.64 | 2019-2023 | |
| Glaxosmithkline, LLC. | $712.47 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $611.34 | 2019-2024 | Farxiga, Fasenra, Breztri |
| Pfizer INC. | $546.43 | 2019-2024 | |
| Abbott Laboratories | $346.49 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $317.17 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $264.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.07 | 2019-2024 | Jardiance |
| Allergan, INC. | $237.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $224.19 | 2019-2021 | |
| Astellas Pharma US INC | $204.61 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.28 | 2019-2023 | Xifaxan |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Brandner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.